Market Overview

IDEAYA Biosciences to Present at the 37th Annual J.P. Morgan Healthcare Conference on Tuesday, January 8, 2019

Share:

SOUTH SAN FRANCISCO, Calif., Jan. 2, 2019 /PRNewswire/ -- IDEAYA Biosciences, Inc., an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics to treat cancer, announced that the company is scheduled to present at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 8, 2019 at 4:30 p.m. PT (7:30 p.m. ET).

About IDEAYA Biosciences
IDEAYA is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics.  Our approach integrates extensive capabilities in identifying and validating translational biomarkers with oral small molecule drug discovery to select patient populations most likely to benefit from our targeted therapies.  We are applying these capabilities across three classes of precision medicine including direct targeting of oncogenic pathways, synthetic lethality – which represents an emerging class of precision medicine targets – and immuno-oncology.  For additional information, please visit www.ideayabio.com.

Investor and Media Contact
IDEAYA Biosciences
Paul Stone
SVP, General Counsel and Head of Operations
pstone@ideayabio.com

IDEAYA Biosciences Logo (PRNewsfoto/IDEAYA Biosciences)

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/ideaya-biosciences-to-present-at-the-37th-annual-jp-morgan-healthcare-conference-on-tuesday-january-8-2019-300771671.html

SOURCE IDEAYA Biosciences, Inc.

View Comments and Join the Discussion!
 
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com